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Abstract
In the era of personalized medical practice, understanding the genetic basis of patient-specific adverse drug reaction (ADR)
is a major challenge. Clozapine provides effective treatments for schizophrenia but its usage is limited because of life-
threatening agranulocytosis. A recent high impact study showed the necessity of moving clozapine to a first line drug, thus
identifying the biomarkers for drug-induced agranulocytosis has become important. Here we report a methodology termed
as antithesis chemical-protein interactome (CPI), which utilizes the docking method to mimic the differences in the drug-
protein interactions across a panel of human proteins. Using this method, we identified HSPA1A, a known susceptibility
gene for CIA, to be the off-target of clozapine. Furthermore, the mRNA expression of HSPA1A-related genes (off-target
associated systems) was also found to be differentially expressed in clozapine treated leukemia cell line. Apart from
identifying the CIA causal genes we identified several novel candidate genes which could be responsible for
agranulocytosis. Proteins related to reactive oxygen clearance system, such as oxidoreductases and glutathione metabolite
enzymes, were significantly enriched in the antithesis CPI. This methodology conducted a multi-dimensional analysis of
drugs’ perturbation to the biological system, investigating both the off-targets and the associated off-systems to explore
the molecular basis of an adverse event or the new uses for old drugs.
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Introduction
Clozapine (CLZ) provides one of the most effective therapeutic
treatments for schizophrenia [1]. It is classified as an atypical
antipsychotic drug because of its binding to serotonergic and
dopamine receptors. However, its usage is limited due to potential
life-threatening adverse drug reaction, mainly agranulocytosis
[2,3,4]. FDA therefore requires blood testing for patients taking
CLZ, complicating the clinical use of the drug. A recent high
impact clinical study demonstrated the necessity of moving CLZ
from a 3
rd line drug to a 1
st line drug based on its overall benefit/
risk ratio [1]. Thus the identification of the biomarkers for
clozapine induced agranulocytosis (CIA) could greatly broaden the
usage of this drug. Organizations such as the severe adverse event
consortium (SAEC) and Duke University are collaborating on
identifying genetic risk factors for CIA via genetic association
studies (http://www.genomeweb.com/dxpgx/saec-duke-collabo-
rate-rare-variants-adverse-events-research). However, due to the
rarity of suitable patients, such an approach requires global
collaboration. Even if some statistically significant SNPs are
identified by using genome wide association studies [5,6],
identifying the causal mechanism of such SNPs and using them
in prediction models still presents a challenge. Instead of the
traditional association study, we proposed an alternative compu-
tational methodology to identify the genetic risk factors for CIA,
by identifying the known risk genes, explaining the relevant
mechanism by observing chemical-protein interactions and
providing a ‘‘most likely’’ candidate list [7] for pharmacogenetic
and pharmacogenomic studies [8].
Drug-induced agranulocytosis is a form of idiosyncratic drug
reaction (IDR). It is dose independent and is a form of serious
adverse drug reaction [9,10,11]. One of the major causes of IDR is
unexpected drug-protein interactions in human proteins
[12,13,14,15,16,17,18]. Olanzapine (OLZ) is a CLZ analog, but
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cause much less agranulocytosis compared with CLZ [19,20,21], a
fact that is also confirmed in our statistical test (Fisher’s exact test
p=8.2E-21, Table 1). Differences in their interaction profile
towards human proteins (off-targets) might explain the etiology of
CIA. Hence we hypothesized that if a human protein tends to be
targeted by CLZ but not OLZ, the protein should be regarded as
the candidate mediator of CIA, and the genes sharing a biological
function with the off-targets (off-system, short for ‘off-target
associated system’) should also display expression perturbation in
cell lines treated by the drug. For example, we identified from a
410 protein target set retrospectively that Hsp70 protein as the off-
target of CLZ but not OLZ, and that genes sharing the biological
function with HSPA1A (Hsp70’s gene) or acting as neighbors in
Human Protein Reference Database (HPRD), a protein-protein
interaction (PPI) database, with HSPA1A were found up-regulated
in cell lines treated by CLZ. Another hypothesis is that if a protein
target is preferably targeted by all drugs causing agranulocytosis
(case) but not targeted by the agranulocytosis- drugs (control), the
protein is a candidate mediator of the agranulocytosis. Using this
hypothesis, we identified NQO2 gene as the candidate gene of
agranulocytosis.
Results
Preparing proteins and chemicals for chemical-protein
interactome
To identify unexpected drug-protein interactions, we utilized
chemical-protein interactome (CPI) [13,22,23], which gives a
score array generated by docking a panel of drug molecules across
a set of human proteins. A CPI delivers two types of information,
the binding conformation and the binding strength (Fig. 1a). It can
be constructed via wet lab techniques [24,25,26,27], but the most
convenient way is to generate an in silico CPI. We used the DOCK
[28] program to evaluate the chemical-protein interaction strength
because it is an open-source software and had been widely used
along with its success in identifying the unexpected chemical-
protein interactions.
To prepare an unbiased protein set, we utilized a pocket set
comprising 410 human protein pockets (381 unique proteins,
Table S1), representing all the available human protein structure
models from third-party target structural databases. The ligand
binding pockets on each protein were then processed manually for
docking preparation (see Methods).
We then mined from literature and the FDA adverse event
reporting system (AERS) the drugs that were reported to cause
agranulocytosis (case) or not cause agranulocytosis (control, Fig.
S1a), aiming at identifying proteins tend to be targeted by case but
not control drugs (red dashed rectangle in Fig. S1b). According to
our criteria (Methods), there were 39 case and 15 control drug
molecules selected for agranulocytosis, including the parent drug
and their major metabolites and isomers. The control drugs did
not share significant 2D structure similarity (Fig. S2), their
indications covering a broad therapeutic categories (covering nine
1
st level of ATC codes). To generate a comprehensive distribution
of docking scores for each protein across many drug molecules, we
also incorporated other drug molecules. Although for effective
performance and classification, a larger data set should be used
[22], e.g., all the FDA approved drugs), we restricted our analysis
to drug molecules from our former studies because of the CPU
time for array docking. Thus, a total of 255 drug molecules,
including the CLZ and OLZ, were selected for docking (Table S2).
Constructing the chemical-protein interactome
Here 255 chemicals were docked into the 410 human proteins
using DOCK, generating a docking score matrix of 2556410
elements. A 2-directional Z-transformation (2DIZ) [23] was then
applied to transform the raw docking score into a Z9-score,
extending the multiple active site corrections concept [29]. The
docking scores were normalized by each drug and then by each
protein (Fig. 1b), thus the ‘‘endogenous’’ variance among proteins,
such as the free energy variation across the binding pockets, has
been normalized and contribute almost zero to the variance of the
Z9-scores (Table S3). The major contributions of the variance are
from the chemical effects and the chemical-protein interactive
effects after the 2DIZ, which means that each chemical can ‘fish’
its targets only based on Z9-score without noises from the
‘‘endogenous’’ variance among proteins.
Binomial antithesis CPI between CLZ and OLZ
A basic assumption in using antithesis binding profile from CPI
between CLZ and OLZ is that, 1) the two drugs are broadly similar
in their effects, except for some side-effects, such as agranulocytosis,
and that therefore, apart from some minor differences, their overall
protein binding profile should be similar; 2) these minor differences
inproteinbindingprofilearehighlylikely tobeassociated with CIA.
To verify the comparability between CLZ and OLZ, we calculated
Table 1. Test for the difference of the agranulocytosis report
rate between clozapine and olanzapine in the FDA adverse
event reporting system (AERS).
Clozapine Olanzapine
Agranulocytosis Reports 185 16
Total Reports 16813 11304
Ratio of Agranulocytosis Report (%) 1.1 0.14
pCLZ-OLZ* 8.2E-21
*Chi-square test for the equal rate of agranulocytosis between CLZ and OLZ.
AERS records were updated in September, 2009.
doi:10.1371/journal.pcbi.1002016.t001
Author Summary
Idiosyncratic drug reactions (IDR) generally cannot be
identified until after a drug is taken by a large population,
but usually result in restricted use or withdrawal. Clozapine
provides the most effective treatment for schizophrenia
but its use is limited because of a life-threatening IDR, i.e.,
the agranulocytosis. A high impact clinical study demon-
strated the necessity of moving clozapine from 3
rd line to
1
st line drug; therefore, intensive research has aimed at
identifying genes responsible for clozapine-induced agran-
ulocytosis (CIA). Olanzapine, an analog of clozapine, has
much lower incidence of agranulocytosis. Based on this
phenomenon, we proposed an in silico methodology
termed as antithesis chemical-protein interactome (CPI),
which mimics the differences in the drug-protein interac-
tions of the two drugs across a panel of human proteins.
e.g., HSPA1A was identified to be targeted by clozapine not
olanzapine. Furthermore, the gene expression of the
HSPA1A-related gene system was also found up-regulated
after clozapine treatment. This approach can examine the
system’s perturbation in terms of both the off-target and
the off-system’s interaction with the drug, providing
theoretical basis for decoding the adverse drug reactions
or the new uses for old drugs.
Off-Target/Off-System Clozapine Adverse Reaction
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vectors of CLZ and OLZ across all 410 human proteins (with
missing values removed). All four CLZ-OLZ pairs (2 CLZ
ionization states62 OLZ ionization states) obtained high positive
PCC values (Fig. S3a). Their mean PCC value was distinctly higher
(p=0.0009 for permutation test in Fig. S3b). The high correlated
Figure 1. Workflow of construction and mining of the binomial antithesis chemical-protein interactome (CPI). (a) Binding
conformations and raw docking scores were derived from the CPI with each column representing the drug molecule and each row representing the
protein. (b) The 2DIZ transformation was applied to the CPI comprising 255 drugs and 410 protein pockets. (c) The OLZ and CLZ columns were
extracted from the CPI where their Z9 score differences for each protein were measured by A-scores. The p values for each achieved A-score were
calculated by simulating a random background. (d) Proteins were ranked according to their p values. In this case, Hsp70 was selected, proteins
belonging to the same biological function (anti-apoptosis system or Hsp70’s neighbor in HPRD network) were selected and then their expression
changes in CLZ treatment were investigated (green bars indicated the rankings of the Hsp70 related genes when ordered by the change after CLZ
treatment) and tested for significance by randomly selecting the same probe number in the genome background for permutation.
doi:10.1371/journal.pcbi.1002016.g001
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structural and pharmacological similarity, which also indicated
the structural variability of all 255 drug molecules in the
construction of the CPI. We therefore hypothesized that the
proteins exhibiting different binding affinity against CLZ and OLZ
might account for the agranulocytosis risk of these two analogs.
In order to identify the minor distinctions, we defined the
antithesis score (A-score) for protein i as the Z9-score difference
between CLZ and OLZ towards protein i,
A
clz,olz
i ~Z0
i,clz{Z0
i,olz:
We also calculated the probability of an A-score less than A
clz,olz
i
between two randomly selected drug molecules among 255
molecules at protein i (Fig. 1c), which could be expressed as,
pi~P(A
j,k
i vA
clz,olz
i )( j,k [ ½0,255 , j=k):
We performed permutations for each target by randomly
selecting drug-pairs and calculating their A-scores 10,000 times.
Here the p value was the one-tailed probability when the A-score of
the drug-pair was less than that of the CLZ-OLZ pair. Targets with
p value less than the 0.05 cutoff are shown in Table 2. For the four
CLZ-OLZ pairs, we chose only the pair that recalled most known
CIA related genes reported in the genetic association studies.
Multiple antitheses CPI between case and control drugs
A chemical-protein interaction with a Z9-score less or greater than
20.48 was defined as interactive or not interactive, respectively. As
indicated inour previous training set [22], Z9-scores above such cutoff
captured 70% of the true bindings and were enriched more than
three-fold as compared with the false binding. For protein i, ai, bi, ci,
and di, denoting the number of interactive (ai or bi) and not interactive
(ci or di) by case or control drug molecules, respectively, were counted
and the relative ratio (RR) was calculated as follows,
RRi~
ai
aizbi

cizdi
ci

:
To identify proteins preferentially interacting with the case
drugs, we performed Fisher’s exact tests for each protein. The
significance (one-sided) for each of the protein pockets with RR
value exceeding one were computed and were used as a measure
to prioritize the potential protein mediating agranulocytosis.
Table 3 shows protein targets with p values less than 0.05.
Table 2. Candidate off-targets/-systems prioritized from binomial antithesis CPI between CLZ and OLZ.
PDB ID
# Target Name Gene Name Z9 (CLZ)* Z9 (OLZ) A-score
p value
for CPI Role
Sys.
Regulation
p value for Sys.
perturbation
1CBS Cellular retinoic acid-binding
protein 2
CRABP2 20.922 1.653 22.575 0.000
1D1T Alcohol dehydrogenase class
4 mu/sigma chain
ADH7 21.191 1.525 22.716 0.000 OR
1IHI_1 Aldo-keto reductase family 1
member C2
AKR1C2 20.781 2.545 23.326 0.000 OR
1IHI_2 Aldo-keto reductase family 1
member C2
AKR1C2 21.605 1.023 22.628 0.000 OR
1OIZ Alpha-tocopherol transfer protein TTPA 21.269 1.171 22.440 0.000
2E8A Heat shock 70 kDa protein 1 HSPA1A/HSPA1B 21.381 0.150 21.531 0.001 up 0.0289
1D2V Myeloperoxidase MPO 22.753 20.646 22.107 0.005 OR
1DB1 Vitamin D3 receptor VDR 20.660 0.748 21.409 0.012 up 0.0139
1MRQ_2 Aldo-keto reductase family 1
member C1
AKR1C1 22.034 0.123 22.158 0.016 OR
1MRQ_1 Aldo-keto reductase family 1
member C1
AKR1C1 21.036 0.601 21.637 0.021 OR
1DHT Estradiol 17-beta-dehydrogenase 1 HSD17B1 21.822 0.158 21.980 0.021 OR
1MUO Serine/threonine-protein kinase 6 AURKA 21.136 0.529 21.665 0.027 up 0.0749
1VJ5 Epoxide hydrolase 2 EPHX2 21.088 0.228 21.315 0.027
4GTU Glutathione S-transferase Mu 4 GSTM4 20.749 1.060 21.809 0.036 GT down 0.2758
1HDR Dihydropteridine reductase QDPR 21.469 0.561 22.030 0.038 OR
1YB5 Quinone oxidoreductase CRYZ 21.212 0.284 21.496 0.039 OR
1CM8 Mitogen-activated protein kinase 12 MAPK12 21.202 0.301 21.503 0.039 up 0.1238
1XF0_2 Aldo-keto reductase family 1
member C3
AKR1C3 20.865 0.441 21.306 0.041 OR up 0.0113
1HMR Fatty acid-binding protein, heart FABP3 20.826 0.270 21.095 0.046 down 0.1968
#An entry name that ends with a number represents the pocket number of its PDB structure.
*The smaller Z9-score represents a higher theoretical interaction strength.
In the ‘‘Role’’ column, OR and GT indicate oxidoreductases and gluthathione metabolism related proteins, respectively.
doi:10.1371/journal.pcbi.1002016.t002
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PDB ID
a Target Name Gene Name a b c d RR p value Role
1I10 L-lactate dehydrogenase A chain LDHA 21 1 18 14 1.697 0.002 OR
2HGS_2 Glutathione synthetase GSS 24 2 15 13 1.723 0.002 GT
2HRB Carbonyl reductase NADPH 3 CBR3 17 0 22 15 1.682 0.002 OR
1KBQ NAD(P)H dehydrogenase quinone 1 NQO1 16 0 23 15 1.652 0.002 OR
1EEM Glutathione S-transferase omega-1 GSTO1 19 1 20 14 1.615 0.004 GT
1SG0_2 Ribosyldihydronicotinamide dehydrogenase quinone NQO2 14 0 22 15 1.682 0.005 OR
1G0X Leukocyte immunoglobulin-like receptor subfamily
B member 1
LILRB1 15 0 24 15 1.625 0.005
2AHE Chloride intracellular channel protein 4 CLIC4 14 0 24 15 1.625 0.005
1DIA Formyltetrahydrofolate synthetase MTHFD1 14 0 25 15 1.600 0.006 OR
11GS Glutathione S-transferase P GSTP1 18 1 21 14 1.579 0.009 GT
1FIE Coagulation factor XIII A chain F13A1 12 0 23 15 1.652 0.010
1Q4O Serine/threonine-protein kinase PLK1 PLK1 13 0 25 15 1.600 0.011
1LJR Glutathione S-transferase theta-2 GSTT2B 8 0 12 14 2.167 0.011 GT
1FPR Tyrosine-protein phosphatase non-receptor type 6 PTPN6 13 0 26 15 1.577 0.011
1HSO Alcohol dehydrogenase 1A ADH1A 13 0 26 15 1.577 0.011 OR
1IHI_1 Aldo-keto reductase family 1 member C2 AKR1C2 20 2 19 13 1.531 0.014 OR
1SG0_1 Ribosyldihydronicotinamide dehydrogenase quinone NQO2 16 1 22 14 1.540 0.020 OR
1IHI_2 Aldo-keto reductase family 1 member C2 AKR1C2 16 1 23 14 1.514 0.021 OR
1D5R Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase
and dual-specificity protein phosphatase PTEN
PTEN 11 0 26 15 1.577 0.022
1XWK Glutathione S-transferase Mu 1 GSTM1 11 0 26 15 1.577 0.022 GT
1TDI Glutathione S-transferase A3 GSTA3 11 0 27 15 1.556 0.023 GT
5GAL Galectin-7 LGALS7 | LGALS7B 11 0 27 15 1.556 0.023
1W7N Kynurenine–oxoglutarate transaminase 1 CCBL1 11 0 28 15 1.536 0.024
2AB6 Glutathione S-transferase Mu 2 GSTM2 11 0 28 15 1.536 0.024 GT
1MQ0 Cytidine deaminase CDA 15 1 24 14 1.484 0.024
1OAT Ornithine aminotransferase, mitochondrial OAT 15 1 24 14 1.484 0.024
1ANG Angiogenin ANG 12 0 27 15 1.556 0.024
1J8F NAD-dependent deacetylase sirtuin-2 SIRT2 12 0 27 15 1.556 0.024
2J0D Cytochrome P450 3A4 CYP3A4 12 0 27 15 1.556 0.024 OR
1XF0_1 Aldo-keto reductase family 1 member C3 AKR1C3 19 2 19 13 1.524 0.027 OR
1I0Z L-lactate dehydrogenase B chain LDHB 19 2 20 13 1.493 0.028 OR
2BX8_3 Serum albumin ALB 17 2 19 13 1.507 0.028
1GOS_2 Amine oxidase flavin-containing B MAOB 20 3 16 12 1.522 0.030 OR
1UKI Mitogen-activated protein kinase 8 MAPK8 18 2 21 13 1.457 0.031
2BXF Serum albumin ALB 18 2 21 13 1.457 0.031
5P21 GTPase HRas HRAS 14 1 24 14 1.478 0.041
1PIN Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 PIN1 9 0 24 15 1.625 0.041
1H0C Serine–pyruvate aminotransferase AGXT 14 1 25 14 1.456 0.043
1A5Y Tyrosine-protein phosphatase non-receptor type 1 PTPN1 14 1 24 13 1.439 0.043
1QMV Peroxiredoxin-2 PRDX2 9 0 27 15 1.556 0.044 OR
1BJ4 Serine hydroxymethyltransferase, cytosolic SHMT1 10 0 29 15 1.517 0.046
2CYK Interleukin-4 IL4 10 0 29 15 1.517 0.046
3DYD Tyrosine aminotransferase TAT 10 0 29 15 1.517 0.046
1HE5_2 Flavin reductase BLVRB 9 0 30 15 1.500 0.049 OR
aAn entry name that ends with a number represents the pocket number of its PDB structure.
In the last column, OR and GT indicate oxidoreductases and gluthathione metabolism related proteins, respectively.
doi:10.1371/journal.pcbi.1002016.t003
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Besides human leucocytes antigen (HLA) markers, three CIA
susceptible genes have been identified in genetic association studies
[30], namely HSPA1A [31], TNF [32] and NQO2 [33]. None of the
HLA proteins were included in our pocket set since they did not
meet our criteria of choosing protein pockets. Proteins coded by
these three susceptibility genes all happen to be included in our
pocket set comprising third party targetable protein databases
(Table S1).
HSPA1A codes the heat shock 70 kD protein 1 (Hsp70 protein,
PDB ID: 2E8A) and has been reported in a high profile journal to
be associated with CIA with its causality in CIA discussed [31]. It
is also well known for its druggability in antitumor drugs [34],
which in general, cause the death of the cell. The gene was
prioritized in our binomial antithesis CPI (Table 2). Significant
binding strength differences between CLZ and OLZ towards
Hsp70 were identified with the binding conformations visualized
in Fig. 2. The CLZ molecule fits deeply into the Hsp70 pocket
(Fig. 2b). By contrast, the methyl group of OLZ was difficult to
accommodate in the narrow pocket using the similar binding pose
as CLZ (Fig. 2c).
We further performed the site-moiety map analysis [35] of the
Hsp70 pocket by examining the moiety preferences of the docked
ligands and the physicochemical properties of the pocket. One van
der Waals-interacting anchor site was identified with three
essential residues (R272, R342 and G339, Fig. 3a). Among the
docked drug molecules, most used the aromatic moiety or
conjugated bonds to interact with this center (Fig. 3b). Theoret-
ically, both CLZ (Fig. 3c) and OLZ (Fig. 3d) should have been
capable of insertion into this pocket, however, the methyl on the
OLZ molecule made it difficult to hold the same binding direction
as that of the CLZ (see molecule structures in Fig. 3c, d). The CLZ
molecule was inserted deep into the pocket and used most of its
conjugated ring system to interact with the R272 and R342 via p-
p interaction. Compared with CLZ, OLZ could not use the
majority of its conjugated system due to steric hindrance caused by
his methyl group. The above findings add evidence to the
hypothesis that the Hsp70 protein was the off-target of CLZ but
not of OLZ.
Ribosyldihydronicotinamide quinone dehydrogenase (coded by
NQO2; PDB ID: 1SG0), the known risk gene for CIA, was
prioritized from the multiple antitheses CPI (Table 3), together
with other 44 proteins with p value less than 0.05. The protein was
preferably targeted by the case but not the control drugs. The
Kolmogorov-Smirnov test of the Z9-scores between cases and
controls showed significant differences on two pockets (p=0.002
and p=0.004 for pocket 1 and 2, respectively). As for the binomial
antithesis CPI, NQO2 protein ranked 37
th among the 410 proteins
(top 9%) when ordered by p value. Although the p value did not
exceed the 0.05 threshold, the A-score was 21.18, indicating that
there were still differences between the interaction strength of CLZ
and OLZ towards this protein.
Myeloperoxidase and NADPH-oxidase are functionally in-
volved in the pathogenesis of the drug-induced agranulocytosis
[36,37]. Myeloperoxidase (PDB ID: 1D2V) was found in Table 2
whereas two oxidoreductases using NADPH as the co-enzyme,
namely Carbonyl reductase NADPH 3 (2HRB) and NAD(P)H
dehydrogenase quinone 1 (1KBQ) were found in Table 3.
We also investigated the genetic polymorphisms of genes coding
Hsp70, NQO2 protein, Myeloperoxidase and NADPH-oxidase.
Some nonsynonymous single nucleotide polymorphisms (SNPs)
were identified but none of these was found to affect the ligand
binding pockets.
Clozapine perturbation on the Hsp70-associated system
Besides bindings between chemicals and proteins, the drug-
target relationship may also be reflected in the expression changes
of genes related to the off-target associated system [38] after
chemical treatment. If the mRNA expression of a set of genes
related to off-target X is significantly changed after drug treatment,
Figure 2. Structural comparison of clozapine and olanzapine towards HSP70 protein. (a) The structural difference between CLA and OLZ.
(b, c) Binding conformation of CLZ and OLZ towards the Hsp70 ligand binding pocket. The whole molecule of CLZ binds deep into the pocket,
leaving the chlorine atom at the surface. However, the major part of the OLZ molecule is not accommodated in the deep pocket due to the steric
hindrance of the methyl on the heterocycle of OLZ. The figures were drawn using PyMOL.
doi:10.1371/journal.pcbi.1002016.g002
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other for their roles in the adverse reaction. Since Hsp70 was
identified as the putative off-target of CLZ, we sought to
investigate whether the CLZ treatment resulted in perturbation
of Hsp70 and the related gene system. We analyzed the data from
Connectivity Map (cMAP) [39], a collection of gene expression
data from drug-treated human cell lines on Affymetrix U133A
microarrays. Cells were treated by particular drug and vehicle
respectively to measure the change of gene expression. One such
drug-vehicle pair was defined as an instance. For all 6,100
instances, 22,283 probes were ranked by fold-change values with
higher fold-change ranked at the top (close to rank 1), forming a
2228366100 matrix. We recruited all four instances (instance
1170, 1289, 2689 and 6188) performed on the human promyelo-
cytic leukemia (HL60) cell line to specifically address the drug
effect of CLZ on the leukocytes. Instances performed on other cell
lines were also investigated.
We then manually extracted genes related to HSPA1A in Gene
Ontology (GO) (Fig. 1d) [40]. HSPA1A was associated with 7 GO
terms in the biological process. As agranulocytosis is basically
the death of neutrophil and is known to be correlated to
apoptosis pathways [41], we choose the term ‘‘anti-apoptosis’’
(GO:0006916) to characterize the role of HSPA1A in CIA. We
selected all human genes linked to this term that collectively
represented the Hsp70 off-system. These genes were mirrored to
probes on microarray (439 probes corresponding to 235 genes).
For each probe, we calculated the average rank of the probe across
four CLZ instances (R9 rank), with higher R9 (closer to rank 1)
indicating generally up regulated status and lower R9 down
regulated status. We compared the R9 of the Hsp70 system and
other genes on the U133A probe set. The anti-apoptosis system
exhibits an R9 distribution quite distinct from that of the genome
background (Fig. 4a), with significantly higher mean R9 than the
random 235 gene set (258 out of 10000 sets showed higher R9,
p=0.0258 for permutation test, Fig. 4b). The general up
regulation of Hsp70 related genes indicates that CLZ treatment
clearly changes the bioactivity of the Hsp70 system in human
HL60 promyelocytic leukemia cells. The Hsp70 off-system’s
perturbation was further confirmed using HSP1A1’s ‘neighbor’ in
HPRD [42] network) following the same procedure as for
investigating the anti-apoptosis system (Fig. 4c,d). Both GO
term-based off-system and the PPI-based off-system corroborate
the important role of Hsp70 in CIA. The cMAP also contains
breast cancer cell line MCF7 and human prostate cancer cell line
Figure 3. Site-moiety map analysis of the Hsp70 pocket. (a) The van der Waals-interacting anchor site with three essential residues (R272, R342
and G339). (b) Percentages of the functional group among all docked drug molecules. The binding conformation of CLZ (c) and OLZ (d) towards this
site. The molecule directions are also indicated in the 2D molecule structures at the top right corner of (c, d). Bottom left of (d) shows the direction of
the OLZ as if it wants to interact using the same pattern as CLZ but significant steric hindrance makes insertion into the pocket in this way difficult.
doi:10.1371/journal.pcbi.1002016.g003
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be detected in these two cell lines. The significant perturbation
could not be detected on other six GO terms of HSP1A1.
Two-dimensional elucidation of the off-targets and the
off-systems after clozapine treatment
The drug-(off) targets interaction and the gene expression
change are the molecular events at two different dimensions after
drug treatment. To get an overview of the systems perturbation of
the off-targets prioritized in Table 2, we investigated the PPI-based
off-systems for them. We did not choose the GO term-based off-
systems because each gene was related to multiple GO terms, and
it was difficult to objectively choose the appropriate GO terms
related to agranulocytosis. Furthermore, using PPI-based off-
systems to study the drug’s perturbation on the biosystems has
been proved to be applicable [43]. Among 17 off-systems, three
were found to be significant perturbed with a permutation p value
less than 0.05 (Table 2), including Hsp70 off-system.
The PPI-based off-systems were then visualized in Fig. 5, where
the gene expression perturbation ‘landscape’ of the off-systems was
shown. These off-systems were found to be connected by several
hub nodes, such as apoptosis associated gene (TP53), the gene
coding Bcl-2-binding protein (BAG1) and the transcriptional
regulator of vitamin D3 receptor (TRIM24) et al. Interestingly,
NQO2 was also found to be involved in HSPA1A off-system and
significantly up-regulated after CLZ treatment. Besides preferably
inhibited by CLZ, most of the oxidoreductases were found down-
regulated or remain unchanged after CLZ treatment. The whole
picture demonstrated that the impact of CLZ on the HL60 cell
line is reflected on the up-regulation of the anti-apoptosis systems
and the inhibition or the down-regulation of the oxidoreductases.
Perspective investigation of the predicted genetic risk
factors of CIA
Interestingly, oxidoreductases were found to be significantly
enriched in prioritized proteins. For example, quinone oxidore-
ductase (PDB ID: 1YB5), an isozyme of the NQO2 protein, also
appears in Table 2. Seventy out of 410 protein pockets (17%) were
oxidoreductases (Table S1). However, as Table 2 shows,
oxidoreductases were significantly enriched (10 out of 19, 53%,
Fisher’s exact test p=6.6E-4). Among targets prioritized by
multiple antitheses CPI (Table 3), 15 out of 44 pockets (34%)
belonged to oxidoreductases (p=7.9E-3). In addition, only 12 out
of 410 protein pockets (3%) were related to glutathione metabolite,
which plays key role in antioxidation. However, as Table 3 shows,
7 out of 45 (16%) were significantly enriched (p=1.2E-3).
Figure 4. Clozapine disturbance effect towards the Hsp70 systems. Compared with the genome background, genes related to anti-
apoptosis (a) or Hsp70’s neighbor in HPRD network (c) were generally up regulated in CLZ treated HL60 cell lines, in terms of higher R9 value. The
mean R9 of anti-apoptosis (b) or Hsp70’s neighbor in HPRD network (d) related gene system was significantly higher than randomly selected genes in
the genome background simulated by permutation test.
doi:10.1371/journal.pcbi.1002016.g004
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Identification of off-targets has potential application in drug
repurposing [44,45] and personalized medicine [13,46]. Com-
pared with the similarity ensemble approach [47] and the naive
Bayesian classifiers approach [48] to off-target identification, both
of which build new drug-protein connections within the space of
the known therapeutic target, the chemical-protein interactome
approach is a step towards analyzing the entire human proteome,
although the available human protein structrome is limited.
Several of the pocket comparison algorithms have also tried to
explore the off-target spaces facing the entire human proteome
[15,17], or tried to map the off-targets onto the pathways [49] or
the metabolic network [50], but our study is the first one
examining the system’s perturbation in terms of both the off-target
identification and the off-system’s gene expression change,
providing candidates for pharmacogenetic and pharmacogenomic
studies, respectively. Further work may combine the off-target and
the off-system in elucidating and predicting adverse drug reactions.
In the retrospective studies, the antitheses CPI recalled the
accredited susceptible genes for CIA. As a complement to genetic
association studies [6], the CPI reveals the possible mechanism of
the CIA based on the drug-protein interaction, the primary step in
drug reaction. The difference between the interaction conforma-
tion and the interaction strength of CLZ and OLZ towards the off-
targets could account for the difference in patients’ susceptibility to
agranulocytosis. Since none of the nonsynonymous SNPs was
found around the ligand binding pocket of the four proteins
reported to be involved in CIA, we deduced that individual
differences in CIA susceptibility could be explained by a variation
in the expression level of the protein. In fact, NQO2 was found to
have lower expression levels in CIA susceptible patients [33]. The
lower expression level in this detoxification enzyme could make
the patient more sensitive to the drug. It is also reasonable to
expect subsequent discoveries (e.g. some genotypes correlated to
Hsp70 or NQO2 expression level) supporting the CLZ off-target
hypothesis, which could lead to biomarker development at
genotype and gene expression level [51] in CLZ therapy.
The reactive oxygen hypothesis is one of the major hypotheses
of agranulocytosis etiology [37]. In our results, CLZ and other
drugs causing agranulocytosis tended to affect the oxidoreductases,
which play an important role in reactive oxygen clearance. For
example, NQO2 protein and myeloperoxidase are key enzymes in
the detoxification of active radicals thus protecting the cells from
drug-induced oxidative and electrophilic stress [52]. Furthermore,
alpha-tocopherol transfer protein is a prioritized target of
clozapine (Table 2). Blocking the transferring of tocopherol,
which is a strong endogenous antioxidant [53], may also explain
clozapine’s impact on the detoxification system. Clozapine can be
oxidized to reactive nitrenium ions [54], which preferably reacts
with sulfhydryl and is detoxified by glutathione. In our results,
glutathione related enzymes were significantly enriched in the
CPI, implying that the drug causing agranulocytosis not only
affected the detoxification system of oxidoreductases, but might
Figure 5. Off-targets and their off-systems’ perturbation after clozapine treatment. The off-targets, the genes involved in the PPI-based
off-systems and the hub genes are in diamond, circle and hexagon shape, respectively. The PPI information from HPRD contains binary PPI and
protein complex, and only the former information is visualized in this figure for brief. Red/green indicates the up-/down-regulation of the gene
expression after clozapine treatment. Oxidoreductases and gluthathione metabolism related protein are in yellow and purple edges, respectively. The
interaction between HSPA1A and NQO1 was highlighted in red line.
doi:10.1371/journal.pcbi.1002016.g005
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detoxification of the major metabolites of CLZ.
Besides the unexpected drug-protein interactions, the expression
change of the off-system may explain CIA etiology. The
perturbation of anti-apoptosis genes by CLZ treatment reflects
the fact that CLZ disturbs cell death pathways by binding with
Hsp70, and the general up regulation of anti-apoptosis genes can
be explained as a feedback towards elevated apoptotic stress
mediated by Hsp70 and the anti-oxidation system, since the
inhibition of oxidoreductases and the perturbation of oxidoreduc-
tase system is a well known mediator of apoptosis [55]. By
breaking the balance of oxidation and reduction, CLZ can
stimulate apoptosis via Hsp70 inhibition and enhanced oxidative
stress. Along with the CPI results, biological effects of CLZ further
support the hypothesis that Hsp70 and oxidoreductases together
with their respective system serve as the off-targets(-systems) of
CLZ and potentially mediate CIA. Since HL60 is derived from
peripheral blood leukocytes, which is a representative cell model
for the immune system, the finding of the systems perturbation in
HL60 cells but not in MCF7 (breast cancer) and PC3 (prostate
cancer) cell lines strengthens the antiapoptosis and the oxidore-
ductases systems’ function in immune related events. In summary,
53% and 34% of prioritized proteins from the CPI are
oxidoreductases, and 16% of the proteins are related to
gluthathione metabolism. These findings suggest a much higher
participation of the detoxification/antioxidant systems in drug-
induced agranulocytosis than previously thought and the off-
targets/-systems identified in this study can represent candidates
for biomarker development in wet-lab experiments and pharma-
cogenetic/pharmacogenomic screening in the future.
However, the 410 binding pocket set is a limited representation
of the entire human proteome. For instance, it does not include
any HLA proteins according to our target preparation criteria,
which may be involved in agranulocytosis as a mediator of the
immune etiology. Drug-HLA interaction was reported to be an
important step determining the drug-HLA specificity in IDR [56].
In our previous study, we have built the abacavir-HLA-B*5701
interaction models for abacavir-induced hypersensitivity [13]. The
identification of the drug-HLA interaction at the F-pocket of HLA
molecules has been cited by several immunologists [57,58]. Since
HLAs have been identified as the key factors in IDRs [5,6,59,60],
the drug-HLA interactome will be systematically studied in future.
Identification of the related genes and the systems is the first step
towards understanding and more importantly, predicting the IDR.
The IDRs were regarded as unpredictable in response to
compounds [61]. In this study, we argue that the IDRs are
predictable, and the challenge of personalized medicine is not to
predict adverse reaction for a compound but for a patient. The
biomarkers could be either the genetic variations causing a binding
affinity change of the drug towards the off-targets [62,63], the
expression level alteration of one gene [33], or the off-systems’
perturbation. Our study demonstrates that beside polymorphisms
around the binding pocket that alter the drug efficacy via a change
in the binding affinity [64,65], the off-system expression change
could also determine individual variability towards the same drug,
suggesting a new way of identifying biomarkers or constructing a
prediction model for personalized medicine. Such an approach
could also be applied to personalized drug repurposing [66,67,68],
where the off-targets and the off-systems accounting for the new
therapeutic area could also be patient specific.
Adverse drug reaction and the new indication are two ‘off-
effects’ of the drug towards human being. So this study will also
illuminate the drug repositioning by, 1) helping explain the mode-
of-action of the serendipitous repositioned drugs via identifying
their off-targets/-systems; 2) predicting the new use for existing
drugs based on their interaction profiles with the off-targets and
their perturbations on the off-systems. For example, one can
recruit the case and the control molecular set for a particular
indication. After identifying the off-targets/-systems using the
methodology in this study, one can predict the indication of a new
compound based on its impact on these newly identified off-
targets/-systems.
Methods
Analysis of the adverse drug reaction report
The reports were downloaded from the FDA’s AERS (http://
www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Surveillance/AdverseDrugEffects/default.htm). This system tracks
adverse events that are voluntarily reported but only the records from
2004 were freely available. All reports bearing CLZ and OLZ as the
primary or secondary suspected drug were counted. The numbers of
agranulocytosis cases were then counted for each drug. We
performed Fisher’s exact test to examine the frequency difference.
Preparing the target set
Protein targets were obtained from third-party protein structure
databases, including a drug adverse reaction target database [69],
a drug-induced toxicity related protein database [70], a therapeu-
tic target database [71] and a protein database for drug target
identification [72]. Every pocket was examined manually when
constructing the target set for DOCK according to the following
criteria. First, the species should be confined to Homo sapiens;
secondly, a co-crystallized ligand must be contained to indicate the
targetable state of the protein; thirdly, the pocket should not
contain missing residues. Spheres whose radii ranged from 1.1–
1.4 A ˚ were generated to fill in the pocket. A grid box was
constructed 3–5 A ˚ from the spheres. EC classifications of the
enzymes were taken from the annotations of UniProt [73]. Finally,
we achieved 410 protein pockets from 384 PDB entries, 74% of
which have the resolution less than 2.5 A ˚.
Choosing the cases and controls for multiple antitheses
CPI
Drugs reported in the PubMed literature (up to September,
2009) as being associated with agranulocytosis were chosen as
candidates and further examined in the AERS administered by the
FDA/Center for Drug Evaluation and Research (http://www.fda.
gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/
AdverseDrugEffects/default.htm). All AERS raw data were down-
loaded from the FDA website and then placed in a relational
database (MySQL 5.1). Accessible data were limited to the period
from Jan 2004 to March 2009. In any adverse event report, only
the primary or the secondary suspected drugs were regarded as
linked to agranulocytosis. The candidates were only included if
the number of reports exceeded 3. The candidates for control
drugs were collected from AERS data, on condition that there
were no reports of agranulocytosis. Candidates were then
confirmed as control drugs only if they had never been co-cited
with agranulocytosis in PubMed literature and the first 10 results
of a Google search (up to September, 2009; with drug name
AND ‘‘agranulocytosis’’ as query term). The major metabolites
and the isomers of the drugs were also included. In the end, 39
case and 15 control drug molecules were selected for agranulo-
cytosis endpoint. These 15 controls do not share significant 2D
structure similarities. The SMILES code of the drugs and their
derivatives was retrieved from PubChem. The 3D conformations
of chemicals were simulated using CORINA. Charges and
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[74].
Choosing the background drug molecules
The background drugs were chosen from the molecules
prepared in our previous studies, including anti-Alzheimer drugs
[22], drugs referred to in the study by Lamb et al [39] on using the
cMap, case and control drugs for rhabdomyolysis, cholestasis,
deafness and Stevens-Johnson syndrome and QT prolongation
[13]. A total of 255 drug molecules, including case and control
drugs for agranulocytosis, were involved in constructing the CPI.
Constructing the CPI
A CPI comprising 255 drugs towards 410 protein pockets was
constructed using the DOCK [28] program controlled by Bash
shell scripts. The parameters for docking corresponded to the
default settings. The 2DIZ transformation [23] was performed
where the docking score matrix was normalized first by one drug
towards the 410 proteins then by one protein pocket towards the
255 drugs. The empirical threshold 20.48 of the Z9-score was set
to distinguish binding and non-binding, based on the findings of
the previous studies [22,23].
Permutation test for the PCC of CLZ-OLZ pairs
To determine the significance level of similarity between four
CLZ-OLZ pairs (2 CLZ ionization states62 OLZ ionization
states) across their protein binding profile, we randomly recruited
10,000 sets with four drug pairs from all 255 drugs in the CPI, and
identified 9 pairs with mean PCC not lower than the mean PCC of
the four CLZ-OLZ pairs.
Microarray data analysis
Suppose there are n genes sharing a specific GO term or linked
to the same hub in the HPRD network. Each probe was
independently ranked according to expression change for each
instance in cMAP, with most up-regulated being at the top. For
the cMAP instance # 1170, 1289, 2689 and 6188, which were the
CLZ-treated instances, we calculated the mean rank R9 of each
probe as
R0~
R1170zR1289zR2689zR6188
4
,
where R1170,R 1289,R 2689 and R6188 indicate the rank in instance
1170, 1289, 2689 and 6188, respectively. For evaluation on the
perturbation status of a system, we randomly recruited 10,000 sets
with n genes, obtaining m sets with mean rank higher than the
object system. The p value was calculated as m/10000.
Locating the polymorphism onto the proteins
Polymorphism information for the genes was retrieved from
dbSNP [75] and UniProt [73]. The ‘coordinations’ of the amino
acid sequence in the PDB files were adjusted to match the
‘coordination’ of dbSNP. The distance between the polymorphism
site and the ligand binding pocket of the protein was visualized on
PyMOL.
Supporting Information
Figure S1 Workflow of construction and mining of the multiple
antithesis chemical-protein interactome (CPI). (a) Determining the
case (AGNL+) and control (AGNL2) drugs from FDA’s adverse
event reporting system and PubMed. (b) A visualization of the
chemical-protein interactome. Proteins that are preferably inter-
acted by case but not control drugs are highlighted in a red dashed
rectangle, these being regarded as the candidates mediating CIA.
(TIF)
Figure S2 Structures of the 15 control molecules.
(TIF)
Figure S3 Similarity of protein binding profile between
Clozapine and Olanzapine. (a). Ordered by positive PCC value,
the four CLZ-OLZ pairs ranked at the top 0.86, 2.51, 16.60 and
17.15 percentile of all possible pairs among 255 drug molecules,
respectively. (b) The background distribution of the mean PCC of
the four drug molecules were generated by randomly recruiting
10,000 sets with four drug pairs among all 255 drugs. CLZ and
OLZ have highly similar protein binding profiles in terms of
significantly high PCC of Z9-score vectors.
(TIF)
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